The Most Treatable Cancer in Dogs
Lymphoma — malignant proliferation of lymphocytes — accounts for approximately 7-24% of all canine cancer and is the most common hematologic malignancy. Multicentric lymphoma (affecting multiple lymph nodes throughout the body) is the most frequent presentation, comprising approximately 80% of canine lymphoma cases. The typical presentation is a seemingly healthy dog with generalized, painless lymph node enlargement discovered by the owner or veterinarian during routine examination.
Certain breeds carry elevated lymphoma risk. Golden Retrievers and Boxers are among the most predisposed, with incidence rates substantially above the general dog population. What makes lymphoma exceptional among canine cancers is its responsiveness to chemotherapy. While most solid tumors in dogs respond poorly or modestly to chemotherapy, lymphoma achieves complete remission rates of 80-90% with multi-agent protocols — a response rate comparable to the best human lymphoma treatments. This responsiveness makes lymphoma a cancer where treatment decisions have an outsized impact on outcome.
Diagnosis and Staging
Accurate diagnosis requires:
- Fine needle aspirate (FNA) of an enlarged lymph node, which typically shows a homogeneous population of large lymphoid cells. FNA is diagnostic in most cases and more cost-effective than excisional biopsy.
- Flow cytometry or immunohistochemistry to determine immunophenotype (B-cell vs. T-cell), which significantly influences prognosis.
- Staging with bloodwork (CBC, chemistry panel), thoracic radiographs, abdominal ultrasound, and bone marrow aspirate to determine disease extent.
Immunophenotype Matters
Aresu (2016) emphasized that immunophenotype is the single most important prognostic factor in canine lymphoma:
- B-cell lymphoma (approximately 60-70% of cases): Better prognosis. Median survival with CHOP chemotherapy is 12-14 months, with 20-25% of dogs surviving 2+ years.
- T-cell lymphoma (approximately 25-30% of cases): Worse prognosis. Median survival with CHOP chemotherapy is 6-9 months, with fewer long-term survivors.
This distinction should be established before initiating treatment because it informs both the expected outcome and the aggressiveness of the treatment approach.
CHOP-Based Chemotherapy
The Protocol
CHOP is an acronym for the four drugs used in the protocol:
- Cyclophosphamide — alkylating agent
- Hydroxydaunorubicin (doxorubicin) — anthracycline antibiotic
- Oncovin (vincristine) — vinca alkaloid
- Prednisone — corticosteroid
The standard canine CHOP protocol (often called the University of Wisconsin-Madison protocol or UW-25) delivers these drugs in rotating fashion over 25 weeks, with each drug given at a specific point in the cycle to maximize tumor kill while allowing bone marrow recovery between treatments. Treatments are typically given weekly for the first 8 weeks, then every other week.
Outcomes
Garrett et al. (2002) and Vail et al. (2013) documented outcomes:
- Complete remission rate: 80-90% (complete disappearance of all measurable disease)
- Partial remission rate: An additional 5-10%
- Median remission duration: 6-8 months (time from achieving remission to relapse)
- Median overall survival: 10-14 months for B-cell lymphoma; 6-9 months for T-cell
- 1-year survival: Approximately 50% for B-cell; 25-35% for T-cell
- 2-year survival: 20-25% for B-cell; less than 10% for T-cell
Side Effects
CHOP chemotherapy in dogs is generally well-tolerated. Dogs experience far fewer side effects than humans receiving equivalent protocols because veterinary dosing prioritizes quality of life:
- Gastrointestinal effects (decreased appetite, mild vomiting, loose stool) occur in 15-25% of cycles, usually mild and self-limiting (24-48 hours)
- Neutropenia (low white blood cells) occurs in 5-10% of cycles, occasionally severe enough to require dose reduction or hospitalization
- Doxorubicin-specific cardiotoxicity is cumulative and limits the total number of doxorubicin doses to approximately 5-6 over a dog’s lifetime
- Cyclophosphamide-associated sterile hemorrhagic cystitis occurs in 5-10% of dogs
- Hair loss occurs primarily in breeds with continuously growing coats (Poodles, Schnauzers, Bichons); most breeds shed and regrow hair normally
The VCOG-CTCAE (Veterinary Cooperative Oncology Group Common Terminology Criteria for Adverse Events) grades side effects on a 1-5 scale. Most CHOP-treated dogs experience Grade 1-2 events that do not require hospitalization.
Alternative First-Line Protocols
Single-Agent Doxorubicin
For owners who cannot manage the logistics or cost of weekly multi-agent chemotherapy, single-agent doxorubicin given every 3 weeks for 5 treatments produces remission rates of 60-75% with median survival of 7-9 months. This is inferior to CHOP but substantially better than no treatment or prednisone alone.
COP (Without Doxorubicin)
The COP protocol (cyclophosphamide, vincristine, prednisone) omits doxorubicin. Remission rates are 60-70% with shorter remission durations (median 4-6 months). COP may be appropriate for dogs with pre-existing cardiac disease where doxorubicin is contraindicated.
Prednisone Alone
Prednisone alone produces a partial response in 40-50% of dogs with lymphoma, with median survival of 1-2 months. It provides temporary palliation but is not considered therapeutic. Importantly, starting prednisone before referral to an oncologist may induce multi-drug resistance that compromises subsequent chemotherapy response.
Rescue Protocols for Relapse
Most dogs that achieve remission with CHOP will eventually relapse. Rescue (second-line) chemotherapy options include:
- Re-induction with the original CHOP protocol: Second remission rates of 40-60%, but remission duration is typically shorter than the first (median 3-4 months)
- Lomustine (CCNU): Single-agent rescue with response rates of 25-40%
- Rabacfosadine (Tanovea): FDA-conditionally-approved specifically for canine lymphoma relapse. Saba et al. (2018) documented response rates of approximately 30% in dogs that had relapsed after at least one prior chemotherapy protocol
- MOPP protocol (mechlorethamine, vincristine, procarbazine, prednisone): Used as rescue in some protocols
Each successive relapse tends to be shorter and harder to treat, as resistant tumor cell populations are selected by prior therapy.
Treatment Cost
CHOP chemotherapy typically costs $5,000-$10,000 for the full 25-week protocol, including the drugs, administration, and monitoring bloodwork. Single-agent protocols cost less ($2,000-$4,000). Rescue protocols add additional costs. Pet insurance coverage for chemotherapy varies by policy.
The Decision Framework
The decision to treat canine lymphoma is not purely medical — it involves quality of life assessment, financial considerations, and owner philosophy about cancer treatment in animals:
- Full CHOP chemotherapy: Best outcomes, highest cost, most time-intensive (weekly visits for 2 months, then biweekly)
- Single-agent or modified protocols: Intermediate outcomes, lower cost and time commitment
- Prednisone only: Short-term palliation (weeks to 1-2 months), minimal cost
- No treatment: Median survival of 4-6 weeks from diagnosis
All of these are valid choices. The veterinary oncology community emphasizes that the goal of canine chemotherapy is quality of life, not cure. Most dogs on chemotherapy maintain normal activity, appetite, and behavior throughout treatment.
Limitations
Long-term cure (greater than 2 years disease-free) occurs in 20-25% of B-cell lymphoma cases but remains the exception rather than the rule. The molecular subtypes of canine lymphoma — which predict response and resistance patterns — are being characterized but are not yet routinely used to guide therapy. Emerging cancer immunotherapy approaches and metronomic chemotherapy protocols may eventually expand the treatment toolkit beyond standard CHOP. Personalized medicine approaches (selecting drugs based on tumor molecular profile) are in early development and may eventually improve outcomes significantly. Nutritional support during treatment is also an active area of interest — evidence on cancer-specific nutrition for dogs suggests dietary modification may influence treatment tolerance and quality of life.
Frequently Asked Questions
What is the survival rate for dogs treated for lymphoma?
With standard CHOP-based chemotherapy (the gold standard), approximately 80-90% of dogs achieve remission. Median survival times range from 10-14 months, with 20-25% of dogs surviving beyond 2 years. Without treatment, median survival is only 4-6 weeks. Lymphoma is considered the most treatable cancer in dogs, though cure is rare.
What does chemotherapy involve for dogs with lymphoma?
CHOP-based protocols use a combination of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) administered over approximately 6 months, typically in weekly sessions that transition to biweekly and then monthly. Each visit involves a brief infusion or injection. Dogs tolerate chemotherapy significantly better than humans, with only 5-10% experiencing side effects requiring hospitalization.
How much does lymphoma treatment cost for a dog?
Full CHOP-based chemotherapy typically costs $5,000-10,000 depending on the dog’s size and the treatment center. Single-agent protocols (prednisone alone or oral chlorambucil) cost significantly less but provide shorter remission times. The cost must be weighed against the documented survival benefit and quality-of-life improvements during remission.
Can lymphoma come back after treatment?
Yes. Most dogs that achieve remission eventually relapse, typically within 6-12 months of completing the initial protocol. Rescue protocols using different drug combinations can achieve second remissions in some cases, but second remission duration is generally shorter than the first. This is why lymphoma is described as treatable but rarely curable.
Bottom Line
Lymphoma is the most chemotherapy-responsive cancer in dogs, with CHOP-based protocols achieving complete remission in 80-90% of cases. However, median survival remains 10-14 months for B-cell lymphoma and 6-9 months for T-cell, with 20-25% of B-cell patients achieving 2-year survival. Dogs tolerate chemotherapy far better than humans, and most maintain normal quality of life during treatment. Establishing immunophenotype (B-cell vs. T-cell) before starting treatment is essential because it significantly affects prognosis and guides treatment intensity.
References
- Garrett LD et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma (Journal of Veterinary Internal Medicine, 2002).
- Vail DM et al. CHOP chemotherapy for the treatment of canine multicentric lymphoma (Journal of Veterinary Internal Medicine, 2013).
- Saba CF et al. Rabacfosadine for relapsed canine B-cell lymphoma (Journal of Veterinary Internal Medicine, 2018).
- Aresu L. Canine lymphoma, more than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma (Frontiers in Veterinary Science, 2016).